Research projects listing
IMPRINT is a network focusing on maternal and neonatal immunization, funded by the UK’s Global Challenges Research Fund (GCRF) which supports challenge-led interdisciplinary research and aims to strengthen capacity for research and innovation within the UK and in developing countries. IMPRINT aims to build a sustainable network of stakeholders from basic science, immunology, vaccinology, social sciences, industry, public health and national and international policy makers, to tackle the challenges in the best use of vaccines in pregnancy and in newborns, and in the long term to improve maternal and newborn health.
A Dose Reduction Immunobridging and Safety Study of Two HPV Vaccines in Tanzanian Girls (DoRIS) trial evaluates immunogenicity and safety of one dose of HPV vaccine in Tanzania. The objective of this trial is to demonstrate non-inferiority of immune responses with 1 dose of HPV vaccine compared with the recommended 2 or 3 doses of the same vaccine by evaluating HPV 16/18-specific seropositivity, antibody avidity and memory B cell responses at M36.
The Pneumococcal Conjugate Vaccine Impact Study (PCVIS) is one of the first population-level studies to look at the impact of a pneumococcal conjugate vaccine (PCV10) programme on childhood pneumonia and pneumococcal disease protection in a low- or middle-income country. It is a partnership between the KEMRI-Wellcome Trust Research Programme, the London School of Hygiene & Tropical Medicine, GAVI and the Government of Kenya.
TracVac builds on the results of a phase I clinical trial (NCT02787109) of an adjuvanted Chlamydia trachomatis vaccine (CTH522; Olsen et al 2015, JID PMID2578320) developed by Statens Serum Institut (SSI), Copenhagen. TracVac (www.trachoma-vaccine.org) is a 4 partner (LSHTM, Imperial College London, Commissariat à l’Energie Atomique et aux Energies Alternatives, Paris and SSI) EU sponsored consortium,
Anthropological Exploration of Facilitators and Barriers to Vaccine Deployment and Administration During Disease Outbreaks (AViD)
Headed by Shelley Lees, project AViD is working across DRC, Sierra Leone, Brazil, India and Uganda, adopting both a top-down and bottom-up approach to exploring vaccine acceptance. The project will take a critical anthropological approach to exploring what actions can be taken to optimise vaccine acceptance during a disease outbreak.
Ebola vaccine projects – EBOVAC1, EBOVAC2, EBOVAC3, EBODAC and EBOMAN – are a series of trials and associated projects which aim to assess a novel two-dose preventive vaccine regimen against Ebola Virus Disease (EVD). In a two-dose vaccine regimen, individuals are given a first dose to prime the immune system, and then a second dose which is intended to enhance the immune response and increase the duration of the response.